Trials / Unknown
UnknownNCT05192512
Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers
A Phase I Study of TQB2928 Injection in Patients With Advanced Cancers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPα (Signal Regulatory Protein Alpha) and enhances the phagocytosis of cancer cells by macrophages. This is a study to evaluate the safety, tolerability and effectiveness of TQB2928 injection in subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2928 injection | TQB2928 injection is a CD47 Blocker. |
Timeline
- Start date
- 2022-01-24
- Primary completion
- 2024-01-01
- Completion
- 2025-01-01
- First posted
- 2022-01-14
- Last updated
- 2022-03-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05192512. Inclusion in this directory is not an endorsement.